TOPIC
PHARMACEUTICAL News & Analysis
Stocks
Our analyst weighs in on the proposed acquisition and Sigma’s capital raise.
Shane Ponraj | 12 December 2023
Stocks
But the tie-up could face significant hurdles, says Morningstar analysts.
Emma Rapaport | 29 September 2021
Stocks
These wide-moat, low-uncertainty names are reliable, writes Susan Dziubinski.
Susan Dziubinski | 10 May 2021
Markets
Will there be a second wave? Can we avoid another shutdown? Could a treatment be used to prevent disease? Morningstar strategists respond.
Morningstar Equity Analysts | 01 April 2020
Stocks
A new Morningstar report identifies which big-name health companies are inoculated against environmental, social and governance risks.
Lex Hall | 10 January 2020
Stocks
These high-quality companies, including Bristol-Myers Squibb, Roche and Imperial Brands, span a broad range of sectors and represent good value at...
Susan Dziubinski | 15 August 2019
Video
These industries are the most undervalued in the US healthcare sector, owing to potential drug pricing reforms coming out of Washington.
Karen Andersen, CFA | 12 August 2019
Stocks
The legalisation of cannabis in Canada has boosted an industry that Morningstar forecasts will grow by nine times through 2030
Lex Hall | 19 July 2019
Stocks
Though Morningstar views the healthcare sectors in both the US and Australia as fairly valued overall, there is a handful of buying opportunities...
Glenn Freeman | 10 July 2019
Stocks
Rising coal prices have boosted Washington H Soul Pattinson's first-half profit, while restructuring has taken a toll on Sigma, and Brickworks sounds...
AAP | 21 March 2019
of 2
Viewing 1 to 10 of 15